Login
$MIRM
$91.58 -$2.41 (2.56%) Live

$MIRM SEC Filings

Filed On Filing
13 Nov 2026 Form 4: Brege Laura, Director

Received 14,167 shares by exercise or conversion ($237K) · Sold 14,167 shares ($1.33M)

12 Nov 2026 144
10 Nov 2026 8-K: Other Events

Announcement that Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at American Association for the Study of Liver Diseases (“AASLD”)

04 Nov 2026 Form 4: Peetz Christopher, Director

Received 20,000 shares by exercise or conversion ($58.7K) · Sold 20,000 shares ($1.8M)

04 Nov 2026 144
04 Nov 2026 144
03 Nov 2026 10-Q
03 Nov 2026 8-K: Results of Operations and Financial Condition

–Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million

26 Oct 2026 8-K: Other Events

Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

19 Oct 2026 Form 4: Howe Jolanda, SVP, GLOBAL CONTROLLER

Received 16,112 shares by exercise or conversion ($310K)

14 Oct 2026 Form 4: Myers Robert Paul, Chief Medical Officer

Granted 40,000 Employee Stock Option (right to buy) · Granted 25,000 Restricted Stock Units

13 Oct 2026 8-K: Other Events

On October 12, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) (“Livmarli”) for the treatment of cholestatic pruritus in patients aged 6 months o...

06 Oct 2026 Form 4: Peetz Christopher, Director

Received 12,197 shares by exercise or conversion ($211K)

28 Sep 2026 8-K: Other Events

On September 25, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) and Incyte Corporation (“Incyte”) announced that the U.S. Food and Drug Administration (“FDA”) approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total ne...

22 Sep 2026 Form 3: Myers Robert Paul, Chief Medical Officer

Holds 55 shares of Common Stock

15 Sep 2026 144
15 Sep 2026 Form 4: Bjerkholt Eric, CHIEF FINANCIAL OFFICER

Received 18,333 shares by exercise or conversion · Sold 9,943 shares ($978K)

08 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

On September 8, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced that, on September 2, 2026, the Company’s Board of Directors appointed Rob Myers, M.D., to succeed Joanne Quan, M.D., as the Company’s Chief Medical Officer, eff...

03 Sep 2026 Form 4: Howe Jolanda, SVP, GLOBAL CONTROLLER

Sold 658 shares ($65.8K)

03 Sep 2026 Form 4: Peetz Christopher, Director

Received 30,000 shares by exercise or conversion ($88.1K) · Sold 30,000 shares ($2.96M)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support